Paul M. Bisaro's most recent trade in Zoetis Inc - Ordinary Shares - Class A was a trade of 1,596 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 19, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 1,596 | 1,596 | - | - | Restricted Stock Unit | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,225 | 24,243 (0%) | 0% | - | Common Stock | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,225 | 0 | - | - | Restricted Stock Unit | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,236 | 23,018 (0%) | 0% | - | Common Stock | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 1,236 | 0 | - | - | Restricted Stock Unit | |
Myriad Genetics, Inc. | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,695 | 40,145 (0%) | 0% | 0 | Common Stock | |
Zoetis Inc - Ordinary Shar... | Paul Bisaro M. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 1,463 | 21,782 (0%) | 0% | - | Common Stock | |
Zoetis Inc - Ordinary Shar... | Bisaro M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 1,463 | 1,212 | - | - | Restricted Stock Unit | |
Zoetis Inc - Ordinary Shar... | M. Bisaro Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,493 | 0 | - | - | Restricted Stock Unit | |
Zoetis Inc - Ordinary Shar... | M. Paul Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,493 | 20,319 (0%) | 0% | - | Common Stock | |
Zoetis Inc - Ordinary Shar... | M. Bisaro Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 1,223 | 1,223 | - | - | Restricted Stock Unit | |
Myriad Genetics, Inc. | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 7,575 | 24,450 (0%) | 0% | 0 | Common Stock | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 1,626 | 2,651 | - | - | Restricted Stock Unit | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 1,626 | 18,826 (0%) | 0% | - | Common Stock | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 1,480 | 1,480 | - | - | Restricted Stock Unit | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2022 | 1,984 | 5,922 (0%) | 0% | - | Common Stock | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2022 | 1,984 | 0 | - | - | Restricted Stock Units | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 2,673 | 4,244 | - | - | Restricted Stock Unit | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 2,673 | 17,200 (0%) | 0% | - | Common Stock | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 1,192 | 6,917 | - | - | Restricted Stock Unit | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Purchase of securities on an exchange or from another person at price $ 0.79 per share. | 16 Aug 2021 | 50,000 | 196,864 (0%) | 0% | 0.8 | 39,500 | Common Stock |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 96,864 | 0 | - | - | Restricted Stock Units | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 96,864 | 146,864 (0%) | 0% | - | Common Stock | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 99,174 | 99,174 | - | - | Restricted Stock Units | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2021 | 2,779 | 14,527 (0%) | 0% | - | Common Stock | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2021 | 2,779 | 5,694 | - | - | Restricted Stock Unit | |
Zoetis Inc - Ordinary Shar... | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 1,431 | 8,473 | - | - | Restricted Stock Unit | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 96,864 | 96,864 | - | - | Restricted Stock Units | |
TherapeuticsMD Inc | Paul M. Bisaro | Director | Purchase of securities on an exchange or from another person at price $ 1.14 per share. | 04 Jun 2020 | 50,000 | 50,000 (0%) | 0% | 1.1 | 57,000 | Common Stock |